선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Accelerated adoption of the Signatera MRD assay across expanded oncology indications, catalyzed by seven pending MolDX coverage submissions rolling over the next 12 to 18 months,.
CMS reimbursement rate reductions, MolDX coverage restriction on oncology surveillance indications, or administrative audit payment delays.
Natera Inc. (NTRA) is rated Sell with a Fair value of $75.94 per share, compared to a market price of $410.35 as of October 2, 2026, representing an implied return of -81.49% and a 440.36% price premium to Fair value.4
We assign a Sell rating to Natera Inc. with a Fair value of $75.94 per share. At the analysis price of $410.35 on October 2, 2026, the shares trade at a 440.36% premium to Fair value and an implied return of -81.49%. For an ordinary equity investor, this gap indicates that current market pricing discounts uninterrupted clinical hypergrowth and rapid margin expansion, leaving zero margin of safety against execution setbacks or reimbursement friction.4
The primary downside risk that would accelerate a negative re-rating is Medicare or MolDX reimbursement rate compression and coverage restriction on oncology surveillance testing. Medicare accounted for 13.6% of FY2025 revenue ($313.6M) and 14.1% of accounts receivable. If CMS delays Local Coverage Determinations or enforces rate resets, average selling prices would compress, immediately depressing operating cash flows ($215,301,000 in FY2025) and pushing GAAP profitability further into the future.67
The principal factor supporting business outperformance is expanding clinical test adoption in oncology and women's health. In Q2 2026, test volume additions expanded by a record 34,000 tests quarter-over-quarter, and consensus estimates project revenue reaching $3,489,955,650 by FY2027. If seven pending MolDX submissions unlock $150 to $200 in incremental ASP and laboratory automation lowers unit sequencing costs, gross margin could progress toward management's 70%+ target, supporting valuation toward Potential value of $134.46.15
Clinical assay volumes demonstrated strong momentum with a record 34,000 sequential test addition in Q2 2026, supporting consensus revenue projections expanding to $3,489,955,650 by FY2027.15
Seven pending MolDX submissions represent an estimated $150 to $200 ASP expansion opportunity rolling over the next 12 to 18 months,, which could accelerate gross margin expansion toward 70%+.5
Operating cash flow reached positive $215,301,000 in FY2025, supported by a balance sheet cash position of $1,076,140,000, insulating core clinical development from near-term liquidity stress.6
Sell. While Natera maintains impressive assay volume momentum and strong clinical validation in molecular diagnostics, its stock price of $410.35 discounts uninterrupted hypergrowth and flawless margin execution. With a fundamental Fair value of $75.94 and Potential value capped at $134.46, the risk-reward profile is deeply unfavorable.4
Natera Inc. is a diagnostics company specializing in cell-free DNA (cfDNA) testing across oncology, women's health, and organ health. Its core clinical offerings include the Signatera molecular residual disease (MRD) assay, Panorama non-invasive prenatal test, and Horizon carrier screening. In FY2025, consolidated revenue reached $2,306,113,000, driven almost exclusively by clinical testing services.
The company's commercial operations are overwhelmingly centered in the United States, which contributed $2,264,265,000, or 98.19% of consolidated FY2025 revenue. Direct product testing generated $2,295,820,000, representing 99.55% of revenue, while licensing and other revenue accounted for $10,293,000. Public reimbursement forms an essential cash inflow, with Medicare accounting for 13.6% of FY2025 revenue and 14.1% of accounts receivable.
Natera faces acute downside vulnerability if regulatory and operational headwinds converge. The company generated an operating loss of -$309,911,000 in FY2025 and net loss of -$208,160,000. While operating cash flow turned positive to $215,301,000, it was heavily underpinned by $354,404,000 in non-cash stock-based compensation, representing 15.37% of revenue and driving ongoing per-share equity dilution. In a stress scenario where Medicare compresses reimbursement across its 13.6% revenue share and laboratory automation efficiencies stall, operating margins would remain stranded 6 percentage points below normalization targets. At a market price of $410.35 as of 2026-10-02, Natera trades at an EV/revenue multiple of 25.28x. A re-rating toward life science and lab peer multiples such as Charles River (4.245x) combined with a 200 bps increase in WACC to 12.40% leaves market equity exposed to severe downside, validating the committee Sell rating and Fair value midpoint of $75.94.
Medicare accounted for 13.6% of FY2025 revenue ($313.6M) and 14.1% of accounts receivable. A CMS rate reset or delay in MolDX surveillance indication approvals reduces realized ASP and slows 5-year revenue growth by 5 percentage points, compressing operating cash flow.7
투자 논리를 약화시킬 수 있는 다섯 가지 변화입니다.
A drop in Medicare revenue share below 10.0% signals adverse Local Coverage Determinations by MolDX or CMS rate resets, directly compressing realized average selling prices and cash collection efficiency.
현재:13.6% of FY2025 revenue ($313.6M)
다음이면 경고< 10.0% of consolidated revenue
Natera has constructed a defensible competitive position within molecular diagnostics and precision oncology, driven primarily by its Signatera minimal residual disease (MRD) assay and women's health screening franchise. Product revenue accounted for $2,295,820,000 in FY2025, or 99.55% of consolidated revenue ($2,306,113,000), demonstrating near-total commercial dependence on direct clinical testing services. The primary structural moat source lies in substantial clinical switching costs: oncologists rely on patient-specific baseline sequencing to track circulating tumor DNA across treatment and remission. Switching an ongoing patient to an alternative assay invalidates serial comparison baselines, entrenching Natera's testing in standard institutional treatment pathways.
Complementing workflow inertia is an extensive intangible asset portfolio comprising proprietary library preparation chemistry, bespoke bioinformatics pipelines, and extensive clinical utility trial evidence. The company's published clinical literature underpins key coverage decisions under Medicare's MolDX program, which contributed 13.6% of FY2025 revenue and 14.1% of accounts receivable. Management maintains seven active coverage submissions in flight or planned, representing an estimated $150 to $200 ASP expansion opportunity over the next 12 to 18 months,. These evidentiary requirements create high regulatory and commercial barriers to entry for unproven diagnostic competitors.
Despite these structural strengths, Natera's moat rating is strictly bounded at Narrow rather than Wide due to unproven economic profitability. In FY2025, operating losses stood at -$309,911,000 and trailing ROIC was negative at -15.96%, substantially trailing its 10.4005% WACC. Furthermore, stock-based compensation of $354,404,000 exceeded total operating cash flow ($215,301,000), and geographic revenue concentration in the United States stands at 98.19% ($2,264,265,000). Until Natera demonstrates sustainable operating leverage and returns on capital above WACC while defending against emerging liquid biopsy platforms, its economic advantage cannot be characterized as wide.
Trailing ROIC stands at -15.96% in FY2025, operating well below the company's cost of capital (WACC of 10.4005%). While consolidated revenue reached $2,306,113,000 in FY2025, Natera generated an operating loss of -$309,911,000 and a net loss of -$208,160,000. The business continues to generate negative economic profits, as invested capital in high-throughput sequencing capacity has yet to demonstrate normalized positive returns above WACC.26
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($75.94). Each row and column shows what Fair value becomes when one assumption moves.
The enterprise cash-flow model projects negative first-year free cash flow; treat the sensitivity grid as provisional and re-check reinvestment assumptions.
In the base case, revenue expands in line with consensus projections at 26.15% in FY2026 and 19.97% in FY2027, before decelerating toward 11.0% by FY2030 as domestic clinical adoption matures. Operating margins transition from -5.5% in FY2026 to positive 2.0% in FY2027 and normalize toward 16.0% by FY2030 as fixed laboratory overhead levers down. Capex scales down from FY2025 peak levels of $106.19M (3.2x D&A) toward maintenance intensity of 9.38% reinvestment rate in FY2030. Medicare reimbursement remains stable at ~13.6% of revenue. Under an equal-weighted synthesis of EV/revenue ($114.97) and FCFF DCF ($36.90) at a 10.40% WACC, Fair value is established at $75.94.1
Accelerating test volume additions and new indication coverage demonstrate robust commercial execution, yet market valuation at $410.35 already discounts hypergrowth far in excess of fundamental value.
Inline operational results confirm established revenue expansion but provide no fundamental catalyst to close the substantial valuation disconnect relative to $75.94.
An earnings miss exposes the fragility of shares trading at $410.35, where negative operating earnings leave no valuation support against multiple compression.
Earnings quality exhibits a marked divergence between reported cash generation and GAAP profitability. Operating cash flow has inflected into positive territory, reflecting improved commercial billing procedures and collection cycles. However, consolidated GAAP operating income and net income remain in deep loss territory, with reported operating cash flow heavily dependent on elevated non-cash stock-based compensation expense rather than true operating earnings. Furthermore, accounts receivable concentration with Medicare has expanded, heightening sensitivity to public reimbursement processing timelines. Demonstrating genuine earnings quality will require converting top-line testing volume into positive GAAP operating profit while moderating shareholder dilution from equity grants.
Clinical test volume expansion is the fundamental driver of top-line revenue growth and fixed laboratory overhead absorption.
Natera's cash flow statement demonstrates an operational inflection alongside heavy capital reinvestment. Operating cash flow improved to positive $215,301,000 in FY2025 after historical deficits, including negative free cash flow of -$286,154,000 in FY2023. However, this cash generation was heavily driven by non-cash stock-based compensation of $354,404,000, which exceeded total operating cash flow. Net capex of $106,188,000 resulted in positive free cash flow of $109,113,000 in FY2025. Working capital remains sensitive to billing collections, as accounts receivable expected from Medicare rose from 11.5% in FY2024 to 14.1% in FY2025.67
Trailing ROIC is negative at -15.96% in FY2025, reflecting an operating loss of -$309,911,000 on $2,306,113,000 of revenue. However, the multi-year trajectory is improving, recovering from operating margins of -74.85% in FY2021 and -41.22% in FY2023 toward -13.44% in FY2025. As laboratory automation projects lower unit sequencing costs and SG&A levers over test volume, operating income is projected to inflect positive by FY2027 ($69.80M), driving ROIC toward double digits by FY2030.
Current ROIC of -15.96% trails Natera's WACC of 10.4005%, representing an economic spread of -26.36 percentage points. The company is actively consuming economic capital, and intrinsic value creation remains contingent upon achieving its target normalized operating margin of 16.0% post-FY2028.
| 매출 | US$2,306,113,000 |
|---|---|
| 매출원가 | US$810,627,000 |
| 매출총이익 | US$1,495,486,000 |
| 영업비용 | US$1,805,397,000 |
| 영업이익 | -US$309,911,000 |
| 영업외 항목 및 세금 | US$101,751,000 |
| 순이익 | -US$208,160,000 |
| 총자산 | US$2,398,344,000 |
|---|---|
| 현금 | US$1,076,140,000 |
| 유동자산 | US$1,496,939,000 |
| 총부채 | US$685,931,000 |
| 유동부채 | US$441,228,000 |
| 주주자본 | US$1,712,413,000 |
출처: SEC EDGAR · 제출일 2026-02-27 · SEC EDGAR
| 사업 범주별 매출 | 매출 | 비중 | 전년 대비 |
|---|---|---|---|
| Product | US$23억 | 99.6% | 36.2% |
| Licensing And Other | US$1029.3만 | 0.4% | -13% |
출처: SEC EDGAR · 제출일 2026-02-27 · SEC EDGAR
| 지역별 매출 | 매출 | 비중 | 전년 대비 |
|---|---|---|---|
| United States | US$22.6억 | 98.2% | 36.6% |
| Europe Middle East India And Africa | US$2448만 | 1.1% | 2.5% |
| Americas Excluding Us | US$935.4만 | 0.4% | 41.3% |
| Other Geographic Areas | US$801.4만 | 0.3% | -7.5% |
2026-10-03 분석에 사용된 시점 재무 데이터입니다.
| 기간 | 매출 | EBITDA | 순이익 | 영업 현금흐름 | 잉여 현금흐름 | 자본적 지출 | 감가상각비 | 주식 기반 보상 | 자사주 매입 | 지급 배당금 | 순부채 발행 | 투자 현금흐름 | 재무 현금흐름 | 기초 현금 | 기말 현금 | 현금 및 투자자산 | 총부채 | 영업이익률 | ROIC | WACC | ROIC−WACC 스프레드 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$2.1억 | -US$9337.4만 | -US$1억 | -US$7405.2만 | -US$9718.8만 | US$2313.6만 | US$617.6만 | US$1060.1만 | — | US$258.9만 | — | US$4702.7만 | US$1318.4만 | — | US$1669만 | US$1.5억 | US$4962.4만 | -47.6% | — | 7.2% | — |
| 2017-12-31 | US$2.1억 | -US$1.3억 | -US$1.4억 | -US$9782.5만 | -US$1.1억 | US$986.7만 | US$714.3만 | US$1140.2만 | — | US$0 | — | US$1378.4만 | US$8037.2만 | US$1669만 | US$1302.1만 | US$1.2억 | US$1.2억 | -64.6% | — | — | — |
| 2018-12-31 | US$2.6억 | -US$1.1억 | -US$1.3억 | -US$7058.1만 | -US$7446.1만 | US$388만 | US$750.1만 | US$1419.8만 | — | — | — | -US$516.1만 | US$1.1억 | US$1302.1만 | US$5100.4만 | US$1.5억 | US$1.2억 | -44.5% | — | — | — |
| 2019-12-31 | US$3억 | -US$1억 | -US$1.2억 | -US$6344.4만 | -US$6841.2만 | US$496.8만 | US$773만 | US$2862.4만 | — | — | — | -US$2.7억 | US$3.4억 | US$5100.4만 | US$6198.1만 | US$4.4억 | US$1.6억 | -38.5% | — | 6.2% | — |
| 2020-12-31 | US$3.9억 | -US$2.1억 | -US$2.3억 | -US$1.8억 | -US$2억 | US$1960.4만 | US$861.3만 | US$5017.1만 | — | US$711.4만 | — | -US$3.3억 | US$5억 | US$6198.1만 | US$4885.5만 | US$7.4억 | US$2.8억 | -55.3% | — | 6.2% | — |
| 2021-12-31 | US$6.3억 | -US$4.5억 | -US$4.7억 | -US$3.4억 | -US$3.8억 | US$4103만 | US$1125.4만 | US$1.2억 | — | — | — | -US$2.1억 | US$5.8억 | US$4885.5만 | US$8461.4만 | US$9.1억 | US$2.8억 | -74.8% | — | 6.3% | — |
| 2022-12-31 | US$8.2억 | -US$5.1억 | -US$5.5억 | -US$4.3억 | -US$4.8억 | US$4769.7만 | US$1670.2만 | US$1.5억 | — | US$3000만 | US$3000만 | US$3.3억 | US$4.8억 | US$8461.4만 | US$4.7억 | US$9억 | US$2.8억 | -66.0% | — | 8.7% | — |
| 2023-12-31 | US$10.8억 | -US$3.8억 | -US$4.3억 | -US$2.5억 | -US$2.9억 | US$3919.9만 | US$2409.7만 | US$1.9억 | — | — | US$0 | US$1.7억 | US$2.5억 | US$4.7억 | US$6.4억 | US$8.8억 | US$2.8억 | -41.2% | — | 8.8% | — |
| 2024-12-31 | US$17억 | -US$1.5억 | -US$1.9억 | US$1.4억 | US$6924.1만 | US$6642.3만 | US$3096.8만 | US$2.7억 | — | — | -US$8.2만 | US$1.4억 | US$3020.4만 | US$6.4억 | US$9.5억 | US$9.7억 | US$1.9억 | -13.1% | — | 9.8% | — |
| 2025-12-31 | US$23.1억 | -US$2.2억 | -US$2.1억 | US$2.2억 | US$1.1억 | US$1.1억 | US$4176.4만 | US$3.5억 | — | — | US$0 | -US$1.3억 | US$4746.1만 | US$9.5억 | US$10.8억 | US$10.8억 | US$2.1억 | -13.4% | — | 9.2% | — |
Natera Inc. (NTRA) trades at 5,000.0x forward earnings against a peer median of 24.8x. Its EV/EBITDA of -259.8x compares with a peer median of 23.9x. The comparison uses 4 peers: Charles River Laboratories International Inc., Moderna Inc., Waters Corporation and Agilent Technologies Inc., as of 2026-10-01 to 2026-10-02.
Diagnostic industry benchmark capex-to-revenue is 4.50% and capex-to-depreciation is 0.80x. Natera's capital expenditures expanded from $39,199,000 in FY2023 to $66,423,000 in FY2024 and $106,188,000 in FY2025, representing 4.60% of revenue ($2,306,113,000) and 3.2x D&A ($41,764,000).6
In a diagnostic bull cycle, clinical guidelines rapidly endorse tumor-informed minimal residual disease testing across major solid tumor histologies, making circulating tumor DNA surveillance routine standard-of-care. Expanding Medicare and commercial payer coverage lifts realized ASPs toward management's $2,000 target, while high-throughput sequencing volume drives automated laboratory economies of scale, elevating gross margins above 70% and accelerating international adoption in markets like Japan,.
In a diagnostic downcycle, commercial payers and public administrators intensify evidentiary thresholds, delay local coverage determinations, and audit historical claims, compressing realized average selling prices. In oncology MRD surveillance, heightened competition from multi-cancer early detection and tumor-naive assay platforms could fragment market share, while sequencing equipment capex commitments strand underutilized laboratory capacity, compounding GAAP losses.
Natera is the undisputed market leader in tumor-informed MRD testing with Signatera, achieving record quarterly test volume additions and outgrowing life science tools peers. Product revenue generated $2,295,820,000 in FY2025 (99.55% of revenue), demonstrating strong market penetration. However, the company remains highly vulnerable geographically, with 98.19% of revenue concentrated in the United States ($2,264,265,000), leaving it directly exposed to domestic regulatory and CMS reimbursement decisions without an international earnings buffer.7
High conviction in the Sell rating is driven by the extreme disconnect between the October 2, 2026 share price of $410.35 and house Fair value of $75.94, representing a 440.36% market premium. The business remains pre-profit with GAAP operating losses of -$309,911,000 and heavy share dilution ($354.40M SBC). Capital preservation dictates a 0% position weighting.46
Risk management centers on capital preservation and recognizing valuation vulnerability. Trading at 25.28x EV/revenue, Natera is priced for flawless execution, perpetual hypergrowth, and seamless MolDX coverage expansions. Investors face fundamental risks including Medicare reimbursement rate resets across its 13.6% revenue stream, persistent stock-based compensation dilution ($354.40M in FY2025), and high stock beta (raw beta of 1.4267). Under our house rating, exposure should be eliminated, avoiding long positions until market prices reconcile with intrinsic cash-flow value.
Despite premium revenue growth (consensus 26.2% in FY2026 vs peer Agilent at 9.0%), the share price of $410.35 as of October 2, 2026 stands 205.18% above our Potential value ceiling of $134.46. The growth premium is fully exhausted, creating an asymmetric downside profile.14
From a fundamental valuation standpoint, Natera remains GAAP unprofitable with an FY2025 operating loss of -$309,911,000. Trading at a 440.36% premium to Fair value ($75.94) and burdened by $354.40 million in annual SBC dilution, the stock offers no margin of safety.6
Natera pays no dividends, reinvests capital aggressively into sequencing infrastructure ($106.19 million capex in FY2025), and carries an implied return of -81.49% to Fair value. Total return and capital preservation mandates require avoiding the shares.6
Sell NTRA. At $410.35 as of October 2, 2026, Natera trades at a 440.36% premium to our Fair value of $75.94, implying an expected return of -81.49%. Market expectations price in uninterrupted hypergrowth and rapid margin normalization, leaving investors exposed to valuation re-rating.4
While test volume growth is robust and FY2025 operating cash flow reached $215.30 million, persistent GAAP operating losses (-$309.91 million in FY2025) and significant stock-based compensation of $354.40 million fail to justify an EV/revenue multiple above 25x. Capital is better allocated to opportunities with favorable risk-adjusted margins of safety.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
In the bear case, competitive liquid biopsy assay entries erode test volume momentum, causing revenue growth to decelerate rapidly. Centralized Medicare and MolDX reimbursement rate reviews compress realized average selling prices across the Medicare revenue stream. Sequencing automation efficiencies fail to materialize, stranding laboratory fixed overhead and leaving GAAP operating margins stalled well below targets. Continued share dilution from stock-based compensation ($354.40M in FY2025) further erodes per-share value, while trading multiples re-rate toward mature laboratory peer benchmarks.
Operating income was -$309,911,000 in FY2025 with gross margin at 64.85% on revenue of $2,306,113,000. If SG&A and sequencing laboratory automation fail to lever down, operating margin stalls 6 percentage points below the 16.0% target, keeping GAAP margins negative.6
Mature peer Charles River trades at EV/revenue of 4.245x and Agilent trades at 6.741x. A 20% contraction from the assumed 5.50x terminal EV/revenue multiple to 4.40x severely reduces exit enterprise value as testing growth normalizes.
Raw beta is 1.4267 and computed WACC is 10.4005%. A 200 bps increase in discount rate to 12.40% sharply depresses the present value of back-loaded cash flows.2
Operating margin stalling worse than -10.0% in FY2027 indicates sequencing laboratory automation and administrative leverage are failing to materialize, delaying operating breakeven beyond multi-year projections.
현재:-13.44% (-$309.91M operating income in FY2025)
다음이면 경고< -10.0% operating margin in FY2027
Capex scaling above 8.0% of revenue indicates facility expansion and sequencer hardware requirements are more capital-intensive than anticipated, permanently impairing FCFF conversion.
현재:4.60% ($106.19M in FY2025; 3.2x D&A)
다음이면 경고> 8.0% of revenue
Deceleration of product revenue growth below 15.0% reveals market saturation in core colorectal and breast indications or competitive share loss in oncology minimal residual disease surveillance.
현재:35.9% YoY growth in FY2025 ($2,295.82M product revenue)
다음이면 경고< 15.0% year-over-year
SBC expanding above 18.0% of revenue signals excessive equity dilution that consumes operating cash flows ($215.30M in FY2025) and destroys per-share intrinsic value for existing equity holders,.
현재:15.37% of revenue ($354.40M in FY2025)
다음이면 경고> 18.0% of consolidated revenue
| high |
| 12 to 18 months |
| Submitting prospective peer-reviewed trial evidence to secure local coverage determinations and broadening commercial payer contracting,.57 |
| Laboratory automation bottlenecks and capex overruns delaying COGS reduction and margin expansion | medium | 12 to 24 months | Executing targeted laboratory automation and workflow optimization projects to lower per-unit sequencing costs toward 70%+ gross margin,.5 |
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (US$3.31) plus discounted terminal value (US$27.61) minus signed net debt per current share (-US$5.98) equals the US$36.90 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
Project revenue, apply a terminal EV/revenue multiple, discount enterprise value, subtract net debt, and divide by diluted shares.
Solve for the growth rate that makes the model value equal the report-date share price.
In the bull case, oncology test penetration and women's health volume accelerate beyond consensus expectations, sustaining strong double-digit annual revenue growth through FY2028. Fixed-cost absorption across high-throughput laboratory facilities drives gross margin expansion toward 70% and enables GAAP operating profitability ahead of expectations by FY2027. Rolling MolDX coverage decisions for pending submissions deliver an estimated $150 to $200 ASP expansion, while international launch in Japan broadens geographic diversification. Capex normalizes rapidly toward maintenance levels, generating substantial positive FCFF.5
Favorable coverage decisions expand realized average selling prices and cash conversion across the oncology surveillance portfolio.
Gross margin expansion reflects the realization of laboratory automation efficiencies and lower unit sequencing costs.
Sustained positive operating cash flow protects balance sheet liquidity and eliminates near-term external capital requirements.
High stock-based compensation dilutes per-share equity value and obscures true economic operating expenses.
| $4.07B |
| $4.61B |
| $5.12B |
| Revenue growth | 26.2% | 20.0% | 16.5% | 13.5% | 11.0% |
| Operating margin | -5.5% | 2.0% | 7.5% | 12.0% | 16.0% |
| Operating income | $-160.00M | $69.80M | $304.95M | $553.79M | $819.61M |
| Tax rate | 0.0% | 0.0% | 10.0% | 18.0% | 21.0% |
| NOPAT | $-160.00M | $69.80M | $274.45M | $454.11M | $647.49M |
| Reinvestment | $80.00M | $99.72M | $73.20M | $56.49M | $60.73M |
| Reinvestment rate (of NOPAT) | -50.0% | 142.9% | 26.7% | 12.4% | 9.4% |
| Free cash flow to firm | $-240.01M | $-29.92M | $201.26M | $397.62M | $586.75M |
| Terminal growth | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
Capital allocation is concentrated entirely on internal organic reinvestment, laboratory facility buildouts, and prospective clinical trials. Capex reached $106,188,000 in FY2025, up from $66,423,000 in FY2024 and $39,199,000 in FY2023, directed at expanding automated sequencing capacity. Natera pays no cash dividends and executes no share repurchases, maintaining a robust liquidity reserve with $1,076,140,000 in cash and short-term investments against total debt of $238,488,000. While this net cash position provides balance sheet resilience, capital discipline must improve regarding non-cash compensation, as $354,404,000 in FY2025 SBC significantly dilutes shareholders to fund operating expansion.
Operating cash flow reached positive $215,301,000 in FY2025 despite a GAAP net loss of -$208,160,000, reconciled primarily through $354,404,000 in non-cash stock compensation.
While cash burn has stabilized, equity holders face annual share dilution of 2-4%, meaning the company is effectively funding operational expansion via equity grants rather than self-sustaining GAAP earnings.
Capex increased from $39,199,000 in FY2023 to $66,423,000 in FY2024 and $106,188,000 in FY2025, representing 3.2x D&A ($41,764,000).
Elevated capital expenditure suppresses near-term free cash flow conversion, but once automation projects conclude, reinvestment rates can normalize toward maintenance levels, supporting future FCFF.
United States revenue was $2,264,265,000 in FY2025, accounting for 98.19% of consolidated revenue ($2,306,113,000), while Medicare contributed 13.6% ($313.6M).
Natera lacks geographic diversification, leaving consolidated revenue and receivables highly exposed to domestic CMS administrative policy shifts and private US payer contract terms.
| 마진 |
|---|
| NTRA | Natera Inc. | $59.1B | 5,000.0x | 21.9x | -259.8x | -12.5% | — |
| CRL | Charles River Laboratories International Inc. | $14.1B | 23.2x | 3.5x | 20.0x | -7.5% | 15.1% |
| MRNA | Moderna Inc. | $76.9B | 34.5x | -39.0% | -5.6% | ||
| WAT | Waters Corporation | $43.1B | 26.6x | 9.3x | 33.1x | 1.9% | 9.4% |
| A | Agilent Technologies Inc. | $47.3B | 24.8x | 6.4x | 23.9x | 21.0% | 25.6% |
| Laboratory workflow automation and next-generation sequencing efficiency gains | positive | Advances in automated liquid handling, next-generation sequencing throughput, and computational biology are systematically lowering per-sample processing costs, enabling molecular diagnostic platforms to expand gross margins toward 70%+ as test volumes scale,. |
| Convergence toward the house Fair value midpoint of $75.94 eliminates the market premium, requiring verification of GAAP operating profitability before considering long entry. |
| Below $40.00 | Assess Margin of Safety Entry | Pricing at or below the DCF floor ($36.90 midpoint) offers an asymmetric margin of safety, provided test volume growth and positive cash conversion remain intact. |
| Quarterly GAAP Operating Loss | Widening beyond -$80M in any quarter | Downgrade operating margin normalization schedule to reflect laboratory automation cost overruns.6 |
| Annual Capital Expenditure to Revenue Ratio | Capex exceeding 8.0% of consolidated revenue | Lower DCF free cash flow projections to account for higher ongoing laboratory capital intensity.6 |
| Consensus Revenue Growth Spread vs Life Science Peers | Spread falling at or below 5.0 percentage points | Compress terminal multiple to mature laboratory peer median of 4.25x-6.74x EV/revenue,.3 |
